Studies of Neuregulin/ERBB Signaling in Human Heart
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDouglas B. Sawyer
About this trial
This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Clinical diagnosis of severe coronary artery disease scheduled to undergo coronary artery bypass surgery.
Disqualifiers
less than 18 years of age
unwilling or unable to provide informed consent
known active myocarditis
hypertrophic cardiomyopathy
Trial population
Subjects with coronary artery disease with scheduled coronary artery bypass surgery.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
The number of highly proliferative clones isolated
Time frame
up to 14 days from isolationSecondary outcomes
1
Flow cytometric ERBB receptor expression in highly proliferative clones isolated from heart tissue
Time frame
up to 14 days from isolationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov